Sorafenib Tosylate (CAS 475207-59-1) Suppliers and Product Information

Sorafenib tosylate is a multi-target antitumor drug used primarily for treating advanced liver cancer, kidney cancer, and differentiated thyroid cancer. It works by inhibiting tumor cell growth and preventing the formation of new tumor blood vessels. The drug acts on multiple kinases, including RAF, VEGFR, PDGFR, c-Kit, and FGFR1.

Frequently Asked Questions

Q: When was sorafenib tosylate approved by the FDA?

A: On December 20, 2005, the Food and Drug Administration (FDA) granted regular marketing approval for sorafenib tosylate 200 mg.

Q: What are the main uses of sorafenib tosylate?

A: Sorafenib tosylate is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of the body.

Q: What are the common side effects of sorafenib tosylate?

A: Common side effects include diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite. More severe side effects may include bleeding gums, blistering or peeling of skin on hands and feet, and difficulty with breathing or swallowing.